A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Eraser</td><td class="align_center">FTO; ALKBH5</td></tr><tr><td class="align_left">Writer</td><td class="align_center">ZC3H13; METTL16; METTL14; METTL3; VIRMA; RBM15B; RBM15; WTAP</td></tr><tr><td class="align_left">Reader</td><td class="align_center">FMR1; YTHDF3; YTHDF2; YTHDF1; YTHDC2; YTHDC1; RBMX; HNRNPC; HNRNPA2B1; LRPPRC; IGFBP3; IGFBP2; IGFBP1</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>N6-methyladenosine (m6A) modification regulators.</div>

Journal of Oncology

tab1

Table 1

Table 1: A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs 